Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cambridge Innovation Capital
BioCentury | Mar 7, 2025
Finance
Strategics back Trimtech’s protein cluster degraders with $31M: Finance Report
Pharma venture arms join founding investors CIC, DDF to back U.K. start-up; plus venture rounds for Garuda, Ataraxis and Callio, and Tenaya’s follow-on
BioCentury | Nov 16, 2023
Deals
Nov. 15 Quick Takes: Kite, Arcellx expand CAR T deal
Plus: Gilde closes new €740M fund and updates from RefleXion, NMD, Lenz-Graphite, Cytovale, T-Therapeutics, Vittoria, CorMedix
BioCentury | Oct 25, 2023
Finance
Oct. 25 Quick Takes: U.K. takes next step in pension fund reforms
Plus: CBC-backed R-Bridge realizes royalty exit, and updates from Akebia, DermBiont, GSK and Flashpoint
BioCentury | Apr 17, 2023
Emerging Company Profile
Complement: taking on Apellis with a gene therapy for geographic atrophy
New target CR1 could shut down complement signaling more fully than Apellis’ C3-targeted therapy
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Dec 15, 2022
Finance
Dec. 14 Quick Takes: Alpha-9 lands $75M for radiopharmaceutical pipeline
Plus: Avidity gains 55% on antibody-oligo conjugate data, and updates from Storm, Avidity, Kymera, Icosavax and more
BioCentury | Dec 3, 2022
Finance
Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal
Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Oct 14, 2022
Politics, Policy & Law
U.K. economic turmoil: a risk and an opportunity
Potential to hasten U.K. pension fund reform amidst sour macroenvironment
BioCentury | Sep 14, 2022
Emerging Company Profile
Pretzel: modulating the mitochondrial genome
Arch-incubated newco launched Monday with $72.5M and three platforms to tackle mitochondrial diseases
BioCentury | Apr 29, 2022
Finance
New CIC fund means more capital for maturing Cambridge ecosystem
Cambridge Innovation Capital raises £225M second fund to write bigger checks, invest in later rounds
Items per page:
1 - 10 of 54